logo

For the Inventor, By the Inventor

Mainz, Germany

Biontech Se


USPTO Granted Patents = 74



Trademarks = 20

Forward Citations = 48

Loading Chart...
Loading Chart...

151 inventors (with patents filed for the assignee):

goldMedal Ugur Sahin (59 out of 195 patents)

silverMedal Friederike Gieseke (14 out of 19 patents)

bronzeMedal David Satijn (13 out of 44 patents)

4.  Alexander Muik (13 out of 15 patents)

5.  Paul Parren (12 out of 136 patents)

6.  Isil Altintas (12 out of 20 patents)

7.  Mustafa Diken (12 out of 21 patents)

8.  Heinrich Haas (11 out of 21 patents)

9.  Sebastian Kreiter (11 out of 27 patents)

10.  Rik Rademaker (8 out of 32 patents)

11.  Andreas Kuhn (7 out of 10 patents)

12.  Kerstin Walzer (6 out of 7 patents)

13.  Tim Beissert (6 out of 12 patents)

14.  Sebastian Hörner (5 out of 5 patents)

15.  Annette Vogel (5 out of 5 patents)


Core Competencies:
RNA
Cancer Treatment
Immunogenicity
Liposomal Formulations
Tumor Antigens
Multispecific Antibodies
Vaccine Development
Therapeutic RNA
Binding Agents
RNA Formulation
Gene Expression
T Cell Activation

74 patents:

1. 12734233 - THERAPEUTIC RNA FOR HPV-POSITIVE CANCER (2026-09-15),
2. 12667621 - RNA FORMULATIONS SUITABLE FOR THERAPY (2026-06-30),
3. 12643930 - IL2 Agonists (2026-06-02),
4. 12637515 - BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF (2026-05-26),
5. 12599660 - THERAPEUTIC RNA FOR HPV-POSITIVE CANCER (2026-04-14),
6. 12522640 - IL2 Agonists (2026-01-13),
7. 12516333 - 3'-UTR SEQUENCES FOR STABILIZATION OF RNA (2026-01-06),
8. 12516104 - Compositions and Methods for Diagnosis and Treatment of Cancer (2026-01-06),
9. 12460198 - Method for reducing immunogenicity of RNA (2025-11-04),
10. 12433911 - Preparation and storage of liposomal RNA formulations suitable for therapy (2025-10-07),
11. 12421319 - Binding agents that bind OX40 (CD134) and method of use thereof to treat disease (2025-09-23),
12. 12419965 - RNA particles comprising polysarcosine (2025-09-23),
13. 12410258 - Antibodies capable of binding to OX40, variants thereof and uses thereof (2025-09-09),
14. 12410221 - Tumor antigens for determining cancer therapy (2025-09-09),
15. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),
Company Overview
BioNTech SE, headquartered in Mainz, Germany, is a pioneering biotechnology company focused on developing innovative RNA-based therapeutics. The company specializes in harnessing the potential of messenger RNA (mRNA) technology for cancer treatment and vaccine development. BioNTech's research encompasses various core technology topics, including immunogenicity, liposomal formulations, tumor antigens, and multispecific antibodies, positioning it at the forefront of the evolving landscape of personalized medicine and immunotherapy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Biontech Se USPTO Patent Assignee Logo
74 Patents

#5 in Mainz

#777 in Germany

#10,121 in the World

Mainz, DE
Mainz, Germany

Biontech Se

Forward Citations = 48

151 inventors:

goldMedal Ugur Sahin (59 out of 195 patents)

silverMedal Friederike Gieseke (14 out of 19 patents)

bronzeMedal David Satijn (13 out of 44 patents)

4.  Alexander Muik (13 out of 15 patents)

5.  Paul Parren (12 out of 136 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biontech Se. Retrieved from https://idiyas.com/company/biontech-se

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…